Related Experiment Video
Updated: Sep 6, 2025
Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
Published on: February 4, 2014
Relaxation of the criteria for entry to the UK Clozapine Central Non-Rechallenge Database: a modelling study
Ebenezer Oloyede1, Eromona Whiskey2, Cecilia Casetta3
1Pharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Insights
Adopting revised US FDA guidelines for clozapine monitoring in the UK could significantly decrease treatment interruptions due to low blood counts, improving outcomes for patients with treatment-resistant psychosis.
Area of Science:
- Psychiatry
- Pharmacology
- Hematology
Background:
- Clozapine is a critical treatment for resistant psychosis.
- UK guidelines mandate clozapine discontinuation for specific hematological thresholds, recorded on the Central Non-Rechallenge Database (CNRD).
- US FDA guidelines were revised in 2015 to allow more flexible clozapine maintenance.
Purpose of the Study:
- To assess the impact of adopting US FDA criteria on clozapine discontinuation in the UK.
- To compare hematological profiles of patients meeting or not meeting FDA discontinuation criteria.
- To evaluate the success rates of clozapine rechallenge in the UK.
Main Methods:
- A modeling study analyzed UK CNRD data from 2002-2021.
- Determined the proportion of UK patients who would discontinue clozapine under FDA criteria.
- Examined hematological characteristics and rechallenge success rates.
Main Results:
- 15% of 3731 UK patients met FDA criteria for discontinuation.
- The median time to CNRD registration was 1.6 years.
- 81% of 519 rechallenged patients had successful rechallenges, with similar rates regardless of prior CNRD criteria.
Conclusions:
- Implementing revised FDA monitoring criteria in the UK could substantially reduce clozapine discontinuation for hematological reasons.
- This policy change may improve patient mental health outcomes without significant physical health risks.
- The findings support greater flexibility in clozapine monitoring protocols.
Background:
Clozapine is uniquely effective in treatment-resistant psychosis. In the UK, patients must discontinue clozapine indefinitely if they are placed on the Central Non-Rechallenge Database (CNRD) after their haematological parameters fall below particular thresholds. Under exceptional circumstances, patients can be rechallenged on clozapine under an off-licence agreement. In the USA in 2015, restrictive practice was discontinued to allow greater flexibility for clozapine maintenance. The absolute neutrophil count leading to treatment interruption was lowered from less than 1·5 × 109/L to less than 1·0 × 109/L and platelet and white cell count monitoring were ceased. We aimed to investigate the implications of a similar policy change on clozapine use in the UK.
Methods:
This was a modelling study of all patients registered on the UK CNRD. First, we determined the proportion of patients placed on the database in the UK who would have had to discontinue clozapine treatment under the US Food and Drug Administration (FDA) criteria. Second, we compared the haematological characteristics of patients who did or did not meet FDA criteria for discontinuing clozapine, including the time to registration from clozapine initiation and the proportion of cases of severe neutropenia at registration. Third, we investigated the success rates of clozapine re-challenge for patients that had been placed on the CNRD. Successful rechallenge was defined as no recurrence of CNRD registration.
Findings:
Between May 2, 2002 and March 1, 2021, 3731 patients were placed on the CNRD, with a mean age of 47 years (SD 15), including 1420 (38%) women and 2311 (62%) men, of whom 3089 (83%) were White, 360 (10%) were Black, 190 (5%) were Asian, and 92 (2%) were classified as other. 566 (15%) of 3731 patients met the equivalent criteria for clozapine discontinuation under the FDA guidelines. The median time to CNRD registration from clozapine initiation was 1·6 years (IQR 0·2-4·9). Data for 519 rechallenged patients were examined; 419 (81%) were successful. Clozapine rechallenge success rates were broadly similar between individuals who did not meet the US CNRD registration criteria (36 [78%] of 46) and those who did meet the criteria (383 [81%] of 473).
Interpretation:
Implementing the revised FDA monitoring criteria in the UK would substantially reduce clozapine discontinuation for haematological reasons, which would greatly improve the mental health outcomes of these patients without having a major effect on their physical health.
Funding:
None.
More Related Videos
09:14Exploring the Neural Correlates of Cognitive Reappraisal in Obsessive-Compulsive Disorder Using Task-based Functional Magnetic Resonance Imaging
Published on: March 14, 2025
10:46A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Related Concept Videos
01:29Psychological and Sociocultural Causes of Schizophrenia
01:26Psychosis: Goals of Pharmacotherapy
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...